MarketPR
A new employment contract for Serina Therapeutics Chief Executive Officer Steve Ledger, executed July 19, 2026 and disclosed via SEC Form 8-K, sets a $500,000 annual base salary and a 50% target annual bonus, lifting the total target cash figure to $750,000 annually.
The Amended and Restated Employment Agreement replaces the prior arrangement dated September 9, 2024. Shares of the Huntsville, Alabama biotech trade on NYSE American as SER.
Base pay and bonus framework Ledger's $250,000 target bonus is tied to annual goals established by the board of directors.
The updated agreement acknowledges his previously granted stock options and preserves his eligibility for further equity awards at board discretion. No specific grant counts or strike prices were disclosed in the filing.
Keep reading